+357 96 030922
info@marketpublishers.com

Global Targeted SSTR Radionuclide Drug Conjugates Supply, Demand and Key Producers, 2026-2032

https://marketpublishers.com/r/G71330ECA406EN.html
Date: May 2026
Pages: 76
Price: US$ 4,480.00 (Single User License)
ID: G71330ECA406EN

Abstracts

The global Targeted SSTR Radionuclide Drug Conjugates market size is expected to reach $ 1326 million by 2032, rising at a market growth of 6.7% CAGR during the forecast period (2026-2032).

Targeted SSTR Radionuclide Drug Conjugates are precision radiotherapeutics designed to deliver therapeutic radioisotopes to tumor tissue by targeting somatostatin receptors, or SSTR. These products are typically composed of an SSTR-targeting peptide or ligand, a chelator, and a therapeutic radionuclide, with 177Lu-labeled agents currently representing the most mature commercialized and clinically applied products. This category is mainly used for the treatment of SSTR-positive gastroenteropancreatic neuroendocrine tumors and related indications. Upstream segments mainly include targeting peptides and precursors, chelators, radioisotope production and purification, sterile radiopharmaceutical filling, and specialized cold-chain logistics, while downstream customers mainly consist of general hospitals with nuclear medicine capabilities, oncology specialty centers, and related radiopharmaceutical distribution systems. On a commercial-market basis, the global Targeted SSTR Radionuclide Drug Conjugates market in 2025 remained concentrated in a limited number of marketed products, and the industry as a whole continued to show the characteristics of limited commercialization, ongoing clinical expansion, and simultaneous manufacturing and supply-chain barriers. Because these products combine the economics of innovative oncology drugs with the operational barriers of radiopharmaceutical manufacturing, including isotope supply, dedicated facilities, quality-release requirements, and specialized distribution, gross margin is generally higher than that of conventional small-molecule drugs and standard injectables. In 2025, the gross margin of commercialized Targeted SSTR Radionuclide Drug Conjugates is estimated to be in the range of 55%-70%.

+357 96 030922
info@marketpublishers.com

At present, the Targeted SSTR Radionuclide Drug Conjugates industry has entered a development stage driven by a limited number of commercialized products while continuing to expand into broader clinical applications. As the clinical value of radioligand therapy in neuroendocrine tumors becomes increasingly validated, targeted SSTR therapy is evolving from a relatively niche specialty treatment into an important segment within radiopharmaceutical oncology. Overall, this field combines the attributes of precision therapy and radiopharmaceutical platform technology. Market attention continues to rise, and the strategic focus of companies is gradually shifting from single-product development toward indication expansion, manufacturing capacity buildout, and global supply network improvement. The market is therefore moving from an early validation phase toward a more stable commercialization stage.

From the perspective of technology and product evolution, the 177Lu route is expected to remain the mainstream direction in the medium term, mainly because it has a stronger clinical foundation, a more established treatment pathway, and a more complete industrial support system. Future development is likely to continue deepening around core indications such as SSTR-positive gastroenteropancreatic neuroendocrine tumors, while also expanding into additional neuroendocrine tumor subtypes, combination treatment strategies, and more refined patient-selection pathways. At the same time, research on novel ligand structures, optimized dosing approaches, and improved theranostic integration is expected to continue. As a result, competition in this market will gradually shift from individual product competition to broader competition in platform capability, clinical resources, and industry-chain coordination.

From an industrialization perspective, the commercialization of Targeted SSTR Radionuclide Drug Conjugates does not depend solely on the drug product itself. It is highly dependent on radioisotope supply, dedicated manufacturing facilities, quality-release systems, cold-chain and time-sensitive distribution capabilities, and the maturity of nuclear medicine infrastructure at the treatment-center level. Compared with conventional oncology drugs, these products place much higher demands on manufacturing and distribution systems. Therefore, leading companies usually advance capacity expansion, regionalized production networks, and treatment-center coverage in parallel. In the future, companies that establish more stable isotope access, more robust manufacturing systems, and broader hospital networks at an earlier stage will be better positioned during industry expansion. This also means that entry barriers and competitive barriers in this field are likely to remain relatively high.

Nevertheless, the industry still faces multiple constraints. First, stable isotope supply,

+357 96 030922
info@marketpublishers.com

the construction cycle of dedicated production capacity, and limited nuclear medicine treatment resources remain important factors restricting further market expansion. Second, patient treatment usually depends on imaging diagnosis, pathological classification, and coordination among specialty centers, while reimbursement systems, hospital access, physician experience, and treatment standards differ across countries and regions, leading to uneven global market development. In addition, as the industry expands toward broader patient populations and more complex treatment regimens, the importance of safety management, long-term follow-up, and standardized treatment pathways will continue to increase. Overall, the Targeted SSTR Radionuclide Drug Conjugates market has clear medium- to long-term growth potential, but its expansion is more likely to take the form of steady growth supported by clinical evidence, supply-chain assurance, and healthcare-system development, rather than rapid short-term scaling.

This report studies the global Targeted SSTR Radionuclide Drug Conjugates demand, key companies, and key regions.

This report is a detailed and comprehensive analysis of the world market for Targeted SSTR Radionuclide Drug Conjugates, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of Targeted SSTR Radionuclide Drug Conjugates that contribute to its increasing demand across many markets.

Highlights and key features of the study
Global Targeted SSTR Radionuclide Drug Conjugates total market, 2021-2032, (USD Million)
Global Targeted SSTR Radionuclide Drug Conjugates total market by region & country, CAGR, 2021-2032, (USD Million)
U.S. VS China: Targeted SSTR Radionuclide Drug Conjugates total market, key domestic companies, and share, (USD Million)
Global Targeted SSTR Radionuclide Drug Conjugates revenue by player, revenue and market share 2021-2026, (USD Million)
Global Targeted SSTR Radionuclide Drug Conjugates total market by Type, CAGR, 2021-2032, (USD Million)
Global Targeted SSTR Radionuclide Drug Conjugates total market by Application, CAGR, 2021-2032, (USD Million)

This report profiles major players in the global Targeted SSTR Radionuclide Drug

+357 96 030922
info@marketpublishers.com

Conjugates market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Novartis, ITM Isotope Technologies Munich SE, Orano Med, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the world Targeted SSTR Radionuclide Drug Conjugates market

Detailed Segmentation:

Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.

Global Targeted SSTR Radionuclide Drug Conjugates Market, By Region:

United States

China

Europe

Japan

South Korea

ASEAN

India

Rest of World

Global Targeted SSTR Radionuclide Drug Conjugates Market, Segmentation by Type:

+357 96 030922
info@marketpublishers.com

Monotherapy Products

Combination Therapy Products

Global Targeted SSTR Radionuclide Drug Conjugates Market, Segmentation by Radionuclide Type:

Beta-emitting

Alpha-emitting

Other

Global Targeted SSTR Radionuclide Drug Conjugates Market, Segmentation by Targeting Vector Type:

Small-molecule

Antibody-based

Other

Global Targeted SSTR Radionuclide Drug Conjugates Market, Segmentation by Application:

Hospital

Specialist Clinic

Other

Companies Profiled:

Novartis

+357 96 030922
info@marketpublishers.com

ITM Isotope Technologies Munich SE

Orano Med

Key Questions Answered

1. How big is the global Targeted SSTR Radionuclide Drug Conjugates market?
2. What is the demand of the global Targeted SSTR Radionuclide Drug Conjugates market?
3. What is the year over year growth of the global Targeted SSTR Radionuclide Drug Conjugates market?
4. What is the total value of the global Targeted SSTR Radionuclide Drug Conjugates market?
5. Who are the Major Players in the global Targeted SSTR Radionuclide Drug Conjugates market?
6. What are the growth factors driving the market demand?

+357 96 030922
info@marketpublishers.com

Contents

+357 96 030922
info@marketpublishers.com

3 WORLD TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES COMPANIES COMPETITIVE ANALYSIS

+357 96 030922
info@marketpublishers.com

4 UNITED STATES VS CHINA VS REST OF WORLD (BY HEADQUARTER LOCATION)

5 MARKET ANALYSIS BY TYPE

+357 96 030922
info@marketpublishers.com

6 MARKET ANALYSIS BY RADIONUCLIDE TYPE

7 MARKET ANALYSIS BY TARGETING VECTOR TYPE

+357 96 030922
info@marketpublishers.com

8 MARKET ANALYSIS BY APPLICATION

9 COMPANY PROFILES

+357 96 030922
info@marketpublishers.com

+357 96 030922
info@marketpublishers.com

List Of Tables

LIST OF TABLES

+357 96 030922
info@marketpublishers.com

+357 96 030922
info@marketpublishers.com

+357 96 030922
info@marketpublishers.com

List Of Figures

LIST OF FIGURES

+357 96 030922
info@marketpublishers.com

+357 96 030922
info@marketpublishers.com

+357 96 030922
info@marketpublishers.com

I would like to order

Product name: Global Targeted SSTR Radionuclide Drug Conjugates Supply, Demand and Key Producers, 2026-2032

Product link: https://marketpublishers.com/r/G71330ECA406EN.html

Price: US$ 4,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:
info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/G71330ECA406EN.html